Abstract: A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient.
Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
Abstract: The present invention provides a fibroblast growth factor heparin-binding analog of the formula: where R1, R2, R3, R4, R5, X, Y and Z are as defined, pharmaceutical compositions, coating compositions and medical devices including the fibroblast growth factor heparin-binding analog of the foregoing formula, and methods and uses thereof.
Type:
Grant
Filed:
February 23, 2006
Date of Patent:
July 24, 2012
Assignees:
BioSurface Engineering Technologies, Incle, Brookhaven and Science Associates
Inventors:
Paul O. Zamora, Louis A. Pena, Xinhua Lin, Kazuyuki Takahashi
Abstract: Soluble molecules are provided. Thus, for example, provided is a soluble molecule which comprises a heterologous amino acid sequence conjugated to a CCR5 amino acid sequence being capable of binding a CCR5 ligand, and wherein the molecule is devoid of an N-terminus domain of CCR5. Also provided are pharmaceutical compositions which comprise the above molecules and methods and uses of same.
Type:
Grant
Filed:
February 18, 2007
Date of Patent:
July 3, 2012
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.
Abstract: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.
Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes.
Type:
Grant
Filed:
July 20, 2006
Date of Patent:
March 13, 2012
Assignee:
Rosalind Franklin University of Medicine and Science
Abstract: The present invention provides an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin, in which the formulation comprises a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent.
Type:
Grant
Filed:
June 7, 2004
Date of Patent:
February 21, 2012
Assignee:
LG Life Sciences, Ltd.
Inventors:
Kyu Chan Kwon, Suk Young Choi, Young Cheol Kang, Hoon Sung Jeh, Seung Joo Lee, Myung Jin Kim, Ji Eon Kim, Jin-Seok Oh
Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Abstract: A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO peptide are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.
Type:
Grant
Filed:
July 8, 2010
Date of Patent:
January 24, 2012
Assignee:
ZymoGenetics, Inc.
Inventors:
Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
Abstract: A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
Abstract: The present invention provides a recombinant nucleic acid encoding a modified cystic fibrosis transmembrane conductance regulator (CFTR) protein. The nucleic acid is modified by the insertion of a first heterologous segment encoding a detectable epitope in a region encoding an extracytoplasmic loop, such as at least one of EL1 through EL6. E12 is currently preferred. Proteins encoded by such nucleic acids, vectors and cells containing such nucleic acids, and methods of use thereof are also described.
Abstract: The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The present invention may further lessen the effect in one or more affected organs in a patient at risk of developing MOF or in one already diagnosed with it.
Abstract: The present invention relates generally to the use of erythropoietin (EPO) to facilitate resuscitation from cardiac arrest. For a mammalian subject suffering from cardiac arrest, concurrent administration of EPO with resuscitation after the onset of ventricular fibrillation facilitates the resuscitation. Administration of EPO serves to attenuate myocardial abnormalities caused by cardiac arrest and the resuscitation efforts and favor improved resuscitation outcomes. The main effect of EPO that facilitates resuscitation is the preservation of left ventricular myocardial distensibility leading to improve left ventricular preload and the amount of blood ejected by chest compression. This effect enables higher coronary perfusion pressures to be generated resulting in a higher rate of return of spontaneous circulation and higher survival rates. The very same effect enables the return of spontaneous circulation to occur faster reducing the time a human subject is in cardiac arrest.
Type:
Grant
Filed:
November 6, 2009
Date of Patent:
November 29, 2011
Assignee:
Rosalind Frankling University of Medicine and Science
Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
Abstract: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof. Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.
Abstract: The present invention provides isolated nucleic acid molecules that encode a substantial part of canine RANKL polypeptide, including the extracellular domains of that polypeptide, the polypeptide and fragments thereof. Vectors and host cells encoding and expressing canine RANKL polypeptide are provided, as well as antibodies that bind to RANKL and that inhibit RANKL activity. Also provided are methods of treating an animal to inhibit or treat the loss of bone minerals.